Traduction de «breast cancer mortality in copenhagen after » (Néerlandais → Français) :

44. Olsen A, Njor HS, Vejborg I, Schwartz W, Dalgaard P, Jensen M-B, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study.
43. Olsen A, Njor HS, Vejborg I, Schwartz W, Dalgaard P, Jensen M-B, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study.

50. Miller Ab TTBCJWC. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.
49. Miller Ab TTBCJWC. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.

19. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.
20. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.

Table 7: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 9: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence

57. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.
56. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Breast cancer (age group 40 - 49): observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)
Breast cancer (age group 40 - 49) : observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)

L. Holmberg en H. Anderson: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped.
L. Holmberg et H. Anderson: HABITS (hormonal replacement therapy after breast cancer - is it safe?); a randomised comparison: trial stopped.

Lancet 363, 453-455 (2004) R.T. Chlebowski en N. Col (Commentary): Menopausal hormone therapy after breast cancer.
Lancet 363, 453-455 (2004) R.T. Chlebowski et N. Col (Commentary): Menopausal hormone therapy after breast cancer.